Hosted on MSN
Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase
Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for ...
Good morning, and welcome to the SELLAS Life Sciences R&D Day. As a reminder, this call is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the ...
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
SELLAS LIFE SCIENCES GROUP I ($SLS) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.08 per share, beating estimates of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results